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Genome-sequencing projects are proceeding at a rapid 
pace and determining the function of open reading ’ 
frames is the next great challenge. Ribozymes with site- 
specific cleaving activity could aid greatly in this process. 
High-throughput screening methods to identify optimal 
target sites for ribozyme cleavage will provide tools for 
functional genomics as well as therapeutic reagents. 
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Introduction 
The versatility of RNA as a form of information storage 
and retrieval is well known. In pioneering work, Cech and 
Altman and colleagues [l,Z] demonstrated that RNA can 
also function as an enzyme, which has created opportuni- 
ties for engineering RNA enzymes (ribozymes) as surro- 
gate genetic tools and for therapeutic applications. 
Engineered ribozymes have several useful attributes, 
including site-specific cleavage of the target RK\;A (and 
hence functional inactivation), multiple turnover, and the 
ability to be exogenously delivered or endogenously 
expressed from an appropriate transcriptional cassette 
[3-S]. Already, ribozymes have proven useful as surrogate 
genetic tools and they are now being examined as thera- 
peutic agents. With the rapid progress in sequence analy- 
ses of genomes, ribozymes are becoming increasingly 
important as tools for studying gene function and identify- 
ing potential new therapeutic targets for the treatment of 
disease. To take full advantage of ribozymes as genetic 
tools and therapeutic agents, new approaches for high- 
throughput functional screening of ribozymes along with 
methods for enhancing intracellular activity are sought. 
Ribozyme usage and catalytic motifs 
Interest in ribozyme technology among the scientific com- 
munity is steadily increasing, as is evidenced by surveying 
the National Library of Medicine database of publications 
in which ribozyme is in the title or is a key word. During 
the last decade there have been over 1800 articles focusing 
on ribozymes, beginning with three listed publications in 
1989 and increasing steadily every year to 335 in 1997. 
The increasing interest in catalytic RN,4s is also reflected 
in the use of ribozymes in several human clinical trials. 
This article will focus upon the simplest catalytic RNA 
found in nature, the hammerhead ribozyme [6,7]. but at 
least five other ribozymes have been demonstrated to 
function as site-specific RNA cleaving reagents: the 
hairpin, group I intron, hepatitis delta, RNAse P and Neu- 
rospora VS RNAs. 
The hammerhead ribozyme has a catalytic core consisting 
of 11 conserved nucleotides flanked by three duplexes 
(Figure 1). Extensive in vitro biochemical analyses of the 
hammerhead ribozyme reaction mechanism have been 
complemented by the acquisition of X-ray crystallographic 
structures [S-10]. The structural studies have verified the 
importance of the conserved catalytic core nucleotides, 
and have provided new information that could be useful 
for the design of trans-acting ribozymes. 
Parameters affecting ribozyme function 
Ribozyme testing in aitro has revealed a number of impor- 
tant considerations for enhancing ribozyme function. The 
factors that should be considered include the lengths of 
the base-pairing regions, the structure of the RNA in the 
region of the cleavage site, the nucleotide(s) at and sur- 
rounding the targeted site of cleavage, the effects of 
various modifications in the ribozyme primary sequence, 
the effects of various backbone modifications on ribozyme 
turnover and stability, and the role of cellular proteins 
[3-$11-153. From such studies, a set of general rules has 
been established concerning the hammerhead ribozyme 
reaction. The reaction is comprised of a series of sequen- 
tial steps: binding of the ribozyme to the target, cleavage, 
and release of the cleavage products [16] (Figure 2). 
Simple principles govern the rate of each step. The rates 
of target binding and the release of each cleavage product 
follow the general rules of nucleic-acid hybridization. The 
cleavage rate (about 1 per minute) is relatively indepen- 
dent of the primary sequence of the binding arms of the 
ribozymes, provided the ribozyme forms stable base pairs 
surrounding the site of cleavage. For optimal ribozyme 
activity in vz’tra, the lengths of the substrate binding arms 
should allow sufficiently stable ribozyme-substrate base 
pairing to facilitate cleavage. yet allow rapid dissociation of 
the cleaved products. Exhaustive mutational analyses of 
the hammerhead ribozyme and its cleavage targets have 
revealed that cleavage can occur after any NUH triplet 
(where N = any nucleotide and H = A, C or U). The kinet- 
ics of the reaction can vary significantly (up to one or more 
orders of magnitude) with different triplet-flanking 
sequence combinations [l&17] so the choice of an appro- 
priate ribozyme cleavage site is the first and most critical 
step in hammerhead ribozyme design. 
In contrast to the rather extensive knowledge of the rules 
governing effective ribozyme function in vitro, we have 
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The hammerhead ribozyme. (a) A representation of the X-ray derived 
structure from Pley et a/. [g]. (b) A generic hammerhead ribozyme 
paired with a substrate RNA. N, any nucleotide; Y, pyrimidine; P, 
purine; H = A,C or U. Roman numerals I, II and Ill refer to the helical 
stems of the ribozyme substrate (1,111) and stem-loop II of the ribozyme. 
only a limited set of rules for predicting ribozyme efficacy 
in an intracellular or in aivo environment. Despite exten- 
sive studies of the parameters that are most likely to influ- 
ence the intracellular functioning of ribozymes (expression 
levels, intracellular co-localization with the target RNA, 
stability of the ribozyme and protein interactions [l&-21]), 
predicting in a& efficacy remains enigmatic? and success- 
ful ribozyme-mediated down-regulation of target RNAs 
relies mainly on empirical testing. The most effective 
strategies for achieving ribozyme function in oivo involve 
mechanisms that maximize the ability of a ribozyme to 
base pair with and cleave the target RNA. For tmns-acting 
ribozymes, base pairing to the target RNAs is the rate-lim- 
iting step in Gr~o [18,19,22]. 
Many studies have employed computer-assisted RNA 
folding to identify sites in RNA that are potentially open 
and accessible to base pairing with a ribozyme. The use of 
such programs does not, however, guarantee successful 
ribozyme functioning within the complex environment of 
a cell because RNAs are continually associated with pro- 
teins from the time of synthesis until they are degraded. 
Some of these proteins can facilitate ribozyme pairing by 
acting as chaperones for RNA interactions, as well as 
ribozyme and target mRNAs subcellular localization 
[14,15,23]. Despite the absence of a well-defined set of 
rules for targeting and expression, several experiments 
demonstrating ribozyme efficacy in GLXJ have been con- 
ducted in model organisms including Drosophda [24], mice 
[25,26] and Zebrafish [27]. These experiments provide 
proof of principle that effective ribozyme use in GJO is a 
possibility for any target. Once well-defined sets of rules 
for ribozyme targeting, expression and intracellular local- 
ization are developed, it should be possible to use 
ribozymes effectively to downregulate any RNA target. 
Therapeutic ribozymes 
HIV infection is the first human disease for which 
ribozymes are being tested as potential therapeutic 
agents (several human clinical trials are currently in 
progress). The simplicity of the sequence requirements 
for hammerhead and hairpin ribozyme cleavage means 
that there are hundreds of potential cleavage sites along 
the length of the viral genome. Because HI\: mutates 
rapidly, and can become resistant to single-drug therapies, 
multidrug and multitarget-site strategies are the most 
effective methods for treating HIV-1 infection. 
Ribozymes therefore represent a reasonable therapeutic 
agent for inhibiting HIV because multiple ribozymes tar- 
geted to a number of different sites in the HIV genome 
can be delivered simultaneously to cells. 
The effective therapeutic use of ribozymes requires their 
effective delivery into the appropriate cells. For example, 
the current ribozyme trials for the treatment of HIV infec- 
tion utilize viral vector-mediated gene-delivery approaches. 
Ribozyme genes encoded within retroviral vector back- 
bones are used to deliver these genes into either ‘I‘ Iympho- 
cytes or hematopoietic stem cells. Thus far, these trials 
have utilized ex v& transduction of cells with the viral 
vectors and subsequent reintroduction into patients. For 
other diseases. delivery to target cells might require the sys- 
temic injection of ribozyme genes or preformed ribozymes. 
At present, the systemic delivery of ribozymes is problem- 
atic because of technical problems in the scaled-up synthe- 
sis of ribozymes and/or viral vectors carrying ribozyme 
genes coupled with the lack of effective and efficient spe- 
cific cell targeting. Methods for effectively delivering 
ribozymes and/or ribozyme genes to cells in nie;o could 
impact greatly on the treatment of a variety of diseases, 
including cancer. Ribozymes that are highly resistant to 
serum and cellular nucleases have already been developed 
[13]. The next challenges are to develop scaled-up syn- 
thetic procedures for these backbone-modified ribozymes 
and new carriers to facilitate delivery and cellular uptake. 
For virsl vector-based delivery, evolving new methods for 
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Figure 2 
Steps in the hammerhead ribozyme reaction. 
Kinetic constants are indicated. The size of 
the arrows for the cleavage step indicates that 
the equilibrium is strongly in favor of cleavage. 
RZ, ribozyme; S, substrate; Pl and P2, 
cleavage products. 
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producing high titer viral stocks with specific cell tropism is 
a challenge for the future. 
New methodologies for identifying ribozyme cleavage sites 
Worldwide efforts to determine the complete nucleotide 
sequence of the human genome as well as the genomes of 
other organisms have resulted in a huge catalogue of 
sequence information, which will continue to increase. The 
goals of the human genome program are to have the project 
completed early in the first decade of the 21” century and 
the following challenge will be to determine the functions 
of tens of thousands of open reading frames. Among the 
techniques that will be utilized for this are antisense-DNA- 
and ribozyme-mediated inactivation of mRNAs expressed 
from these genes. Targeted transcript inactivation can be 
followed by phenotypical and more detailed physiological 
and biochemical analyses of cells in which the target has 
been destroyed. Ribozymes are especially attractive tools 
for targeted inactivation because judiciously chosen cleav- 
age sites will allow discrimination between point mutations 
or related sequences within gene families. 
To realize the full potential of ribozymes in studies of gene 
function as part of the human genome sequence program, 
it is imperative that high-throughput screening methods 
are developed to identify optimal ribozyme cleavage sites. 
As it is not possible to predict the effect cellular proteins 
will have on ribozyme-target interactions, approaches 
need to be developed that will allow ribozyme cleavage 
sites to be rapidly identified in mRNAs in their native, 
protein-associated state. The studies of Lieber and Strauss 
[ZZ] and our own studies [B] have begun to address this 
problem by identifying sites on native mRNAs that are 
accessible to base pairing and hence ribozyme- and anti- 
sense-mediated destruction. The approach of Lieber and 
Strauss [Z’Z] uses libraries or ribozymes with random 
sequences in the binding arms. Successful ribozymes are 
sorted out via their cleaved targets using RT-PCR and 
subsequent cloning, which is a rather laborious process. 
Alternative methods should involve combining random 
library approaches with RNA-based, ligation-mediated 
PCR methods for identifying cleavage sites [29,30]. 
There is a need for the development of high-throughput 
systems for screening and identifying optimal sites for 
ribozyme cleavage. Ideally, these screening methods will 
use intact cells or cell extracts harboring target mRNAs of 
interest. As random approaches provide the greatest range 
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Ribozyme library screening process, The ribozyme library, made 
synthetically or biochemically, is added to cells or cell extracts (i). 
Ribozymes are allowed to find targets and cleave. The cleavage sites 
along the target of interest are identified by amplifying the cleaved 
RNAs using a specific primer complementary to the RNA of interest, 
and a primer added to the cDNA using a ligation step (ii) [29,301. The 
cleavage sites are identified following gel electrophoresis of the 
amplified products as described previously [29,30]. The entire 
procedure could be carried out robotically. 
of possibilities, they are preferred over more directed 
approaches. Methods need to be developed that allow 
rapid, unambiguous identification of ribozyme target 
sequences. Once such sites have been identified, specific 
ribozymes must be tested efficiently in the appropriate cell 
culture or animal model. Given that the ribozyme-target 
pairing interaction can be the rate-limiting step in o&, 
thoughtful consideration must be given to the length of the 
pairing arms in a random library approach. An example is 
provided below for a ribozyme capable of forming ten base 
pairs with the target RNA. A semi-random sequence would 
identify NUH sites (N = any base, and H = A, C or I’). As 
an example of such a pool, a library consisting of ribozymes 
5’-NNNNS-catalytic core-ANNNN-3’ would contain 
2 x 10” different ribozyme sequences. Screening with this 
pool involves de-convoluting either the successful 
ribozymes or the targets that are cleaved. The longer the 
binding arms, the larger the pool size and the more difficult 
the de-convolution task. The challenges of using the 
random or even the semi-random ribozyme approach are to 
incorporate a rapid throughput ribozyme delivery with the 
use of very sensitive assays for ribozyme or ribozyme cleav- 
age site identification. For large-scale functional genomic 
studies, this process should be carried out robotically A pos- 
sible scheme for this entire process is shown in Figure 3. 
Aside from the use of ribozymes in elucidating gene func- 
tion, it is possible that ribozymes used for genomics 
studies can be developed further as therapeutic agents for 
the treatment of diseases associated with altered expres- 
sion or mutant forms of the gene in question. Other 
prospects for therapeutics are perhaps more indirect. I f  the 
ribozyme approach identifies a candidate sequence for 
some disease process, then the product of this gene can be 
used as a target for small-drug therapy. The effective use 
of ribozyme technology in functional genomics will have 
an impact on many other areas of science and medicine. 
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